Biopharma Insights

Insilico Medicine Unveils nach0: A Comprehensive LLM for Chemical and Biomedical Applications

Insilico Medicine, a clinical-stage AI-driven drug discovery company, in collaboration with NVIDIA, has introduced nach0, a novel large language model …

Continue ›››

4 Biotech Startups Developing Breakthrough Drug Modalities

In the dynamic world of drug discovery, companies must continually innovate beyond their existing drug portfolios and modalities. Relying solely …

Continue ›››

The Growing Impact of AI in Healthcare

The advent of artificial intelligence (AI) in healthcare has catalyzed an epoch of change, reshaping diagnostic procedures, therapeutic strategies, and …

Continue ›››

From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development

Drug development for rare (also referred to as orphan) diseases is notoriously challenging. Legislative initiatives, such as the 1983 US …

Continue ›››

Optimising Drug Discovery R&D with Graphs

Data in Life Sciences expert Dr Alexander Jarasch on a new wave of advanced data handling techniques that point the …

Continue ›››

How Industry Embraces Organ-on-Chips: A 2024 Status Report

Report highlights: We are currently at an exciting juncture where several big pharmaceutical companies have started adopting such models and …

Continue ›››

How AI Empowers Biomarker-Driven Clinical Trials

Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving …

Continue ›››

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often …

Continue ›››

Navigating the Brain-Computer Interface Frontier: An Interview with ex-NASA Expert

In a detailed interview, Dr. Brian Jamieson, founder and CTO of Diagnostic Biochips (DBC), delves into the evolving landscape of …

Continue ›››

It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?

The year 2012 is often regarded as the beginning of the deep learning revolution.  That year, Alexnet, the deep learning …

Continue ›››

NVIDIA Introduces New Software Tools for Biopharma AI Applications

NVIDIA's CEO, Jensen Huang, recently outlined the company's expanded focus on software solutions designed to facilitate the adoption of artificial …

Continue ›››

Notable Trends and Companies to Follow in Neuroscience

Historically, the approval rate for medicines treating central nervous system (CNS) disorders was low. By 2022, the success rate for …

Continue ›››